AI-Designed Drug Enters Trials for Rare Neurological Disorders

CAMBRIDGE, Mass. & SHANGHAI – March 02, 2026 – A new chapter in the fight against rare neurological diseases opened today as biotech firm ReviR Therapeutics announced the first human dosing in a Phase 1 clinical trial for RTX-117, a novel drug candidate developed for two devastating conditions that currently have no cure. The milestone is a significant validation for the artificial intelligence and robotics platforms from XtalPi and ReviR that co-discovered and optimized the molecule, demonstrating how technology is accelerating the search for treatments for underserved patient populations.

RTX-117 is an investigational small molecule therapy aimed at Charcot-Marie-Tooth disease (CMT) and Vanishing White Matter disease (VWM), two progressive genetic disorders with profound unmet medical needs. The Phase 1 trial, which has begun in China, will evaluate the drug's safety, tolerability, and how it is processed by the body in healthy participants. This initial study is a crucial first step toward future trials in patients and follows the drug's clearance from both Chinese regulators and the U.S. Food and Drug Administration (FDA), which also granted it Orphan Drug Designation for CMT.

A New Hope for Untreatable Diseases

For thousands of families worldwide, the advancement of RTX-117 represents a tangible beacon of hope. The diseases it targets, while rare, inflict life-altering and often tragic consequences with no approved disease-modifying therapies available.

Charcot-Marie-Tooth disease (CMT) is one of the most common inherited neurological disorders, affecting approximately 1 in 2,500 people. It is characterized by progressive damage to the peripheral nerves that connect the brain and spinal cord to muscles and sensory organs. This leads to debilitating muscle weakness and atrophy, primarily in the limbs, causing difficulty with walking, balance, and fine motor skills. While many patients have a normal life expectancy, they face a lifetime of progressive disability and pain, relying on physical therapy, orthopedic devices, and pain management just to maintain a quality of life.

Vanishing White Matter disease (VWM) is an even rarer and often more catastrophic condition. Primarily affecting children, VWM is a progressive leukodystrophy where the brain's white matter—critical for nerve signaling—deteriorates over time. This leads to a loss of motor control, spasticity, and cognitive decline. A cruel feature of VWM is that periods of stress, such as a fever, infection, or minor head trauma, can trigger episodes of rapid and severe neurological deterioration. For many young patients, the prognosis is grim, with the disease frequently proving fatal.

The complete absence of therapies that can halt or reverse the underlying pathology of either disease underscores the critical need for innovation. RTX-117, as a potential first-in-class therapy, aims to address the root biological cause rather than just managing symptoms.

The AI Engine Rewriting Drug Discovery

The rapid journey of RTX-117 from a computer algorithm to a clinical candidate is a testament to the transformative power of artificial intelligence and robotics in pharmaceutical R&D. The drug was born from a collaboration between ReviR Therapeutics' proprietary VoyageR AI platform and XtalPi's integrated AI and robotics drug discovery engine.

Founded by MIT physicists, XtalPi has built a platform that combines quantum physics-based calculations, sophisticated AI algorithms, and a high-throughput automated robotics lab. This system can digitally design and screen billions of potential molecules, predict their properties with high accuracy, and then physically synthesize and test the most promising ones in a rapid, iterative loop. This 'Design-Make-Test-Analyze' cycle dramatically shrinks the timeline and cost associated with traditional drug discovery, a process that can take over a decade and cost billions.

ReviR's VoyageR AI platform complements this by specializing in the complex biology of RNA, allowing researchers to design small molecules that can precisely modulate RNA function—a notoriously difficult class of targets. By combining these powerful platforms, the companies were able to identify and optimize RTX-117 to act on a complex biological pathway implicated in both CMT and VWM.

"RTX-117's progress exemplifies how AI-driven precision drug discovery overcomes traditional economic barriers in rare disease R&D," said Dr. Shuhao Wen, Chairman of XtalPi. "Our platform's ability to rapidly translate biological discoveries into clinical candidates opens new frontiers for patients and partners."

Unlocking a Novel Biological Pathway

At the core of RTX-117's innovative approach is its target: the Integrated Stress Response (ISR) pathway. The ISR is a fundamental cellular mechanism that helps cells survive under stress conditions by temporarily shutting down the production of most proteins. While this is a protective response in the short term, chronic activation of the ISR—as seen in VWM and other neurological disorders—can become toxic, impairing cell function and leading to cell death.

RTX-117 is designed to act as a molecular 'reset button' for this pathway. It works by activating a key protein called eIF2B, which is a master regulator of protein synthesis. By activating eIF2B, the drug aims to counteract the effects of the overactive stress response and restore the cell's ability to produce essential proteins, thereby addressing the underlying molecular pathology of the disease. This mechanism is considered a highly promising strategy in the neuroscience community for a range of neurodegenerative conditions linked to ISR dysfunction.

Navigating the Global Path to Patients

The strategic execution behind RTX-117's development highlights the growing importance of global collaboration in biotechnology. Securing Investigational New Drug (IND) clearance in both the United States and China allows the companies to conduct clinical trials in two of the world's largest markets simultaneously. This dual-track approach can accelerate patient recruitment—a common challenge for rare diseases—and generate a more robust and diverse data set for regulators.

Furthermore, the Orphan Drug Designation granted by the U.S. FDA provides critical incentives that de-risk the development of therapies for rare conditions. These benefits, including seven years of market exclusivity post-approval and tax credits for clinical testing, make it more commercially viable for companies to invest in treatments that might otherwise be neglected.

"The initiation of dosing in our first-in-human study, coupled with the dual IND clearance in China, marks a transformative leap for ReviR Therapeutics," added Peng Yue, PhD, CEO of ReviR. "By leveraging our VoyageR AI platform and our integrated cross-border operations in the U.S. and China, we are accelerating the development of our small molecule pipelines designed to address critical gaps where no approved disease-modifying treatments exist."

The collaboration between XtalPi and ReviR is advancing multiple programs aimed at systematically tackling rare diseases. The successful clinical entry of RTX-117 serves as powerful validation for their AI-driven approach, demonstrating its potential to not only accelerate scientific discovery but also to deliver new therapeutic options for patients who have been waiting far too long.